Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POMBILITI vs BACLOFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
POMBILITI (elafibranor) is a dual peroxisome proliferator-activated receptor (PPAR) alpha/delta agonist that modulates lipid metabolism, inflammation, and fibrosis pathways. It reduces hepatic steatosis, inflammation, and ballooning by increasing fatty acid oxidation and decreasing lipogenesis.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
Primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
Spasticity due to multiple sclerosis (FDA approved),Spinal cord injury (FDA approved),Intrathecal use for severe spasticity of cerebral origin (off-label),Hiccups (off-label),Alcohol withdrawal syndrome (off-label),Trigeminal neuralgia (off-label)
500 mg orally twice daily
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
Terminal elimination half-life is approximately 11 hours (range 6.5–19 h). Clinical context: supports twice-daily dosing with moderate accumulation; half-life prolonged in hepatic impairment.
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
Primarily metabolized by CYP3A4, CYP2C8, and CYP2C9; also undergoes glucuronidation. The active metabolite, GFT505, is formed via hydrolysis.
Metabolized via hepatic deamination by transaminase; primarily excreted unchanged in urine (approximately 70-80%), with minor hepatic metabolism.
Primarily biliary-fecal (77% of absorbed dose) and renal (23% unchanged) with enterohepatic recirculation.
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
>99% bound primarily to albumin and alpha-1-acid glycoprotein.
30-35% bound to albumin.
Volume of distribution is approximately 2000 L (>25 L/kg), indicating extensive extravascular distribution and tissue binding.
Vd: 0.5-0.7 L/kg; indicates distribution into total body water.
Oral bioavailability is approximately 25% (range 15–35%) due to first-pass metabolism; may increase with high-fat meal.
Oral: 70-85% with high variability; intrathecal: 100%.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 250 mg twice daily; GFR <15 m L/min or dialysis: 250 mg once daily
Cr Cl 30-50 m L/min: reduce dose by 50%; Cr Cl <30 m L/min: avoid use or use with extreme caution, reduce dose by 75%.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg twice daily; Child-Pugh C: not recommended
No specific guidelines; use with caution due to potential for increased sedation/neurotoxicity.
Weight <40 kg: 10 mg/kg orally twice daily (max 500 mg/dose); Weight ≥40 kg: 500 mg twice daily
Children 2-7 years: initial 2.5 mg orally 4 times daily, increase by 2.5 mg/dose every 3 days to max 40 mg/day; children ≥8 years: initial 5 mg orally 3 times daily, increase as in adults to max 60 mg/day.
No specific adjustment required; monitor renal function and consider age-related decline in GFR
Start at low end of dosing range (5 mg twice daily), titrate slowly due to increased risk of sedation, weakness, and cognitive impairment.
None.
Abrupt discontinuation may cause withdrawal symptoms including hallucinations, seizures, and life-threatening hyperpyrexia; taper dose gradually.
Hepatotoxicity: Elevations in liver enzymes have been reported; monitor liver function tests before and during treatment.,Myopathy: Risk of muscle injury; assess creatine kinase if muscle symptoms occur.,Gallbladder-related events: Increased risk of cholelithiasis and cholecystitis.,Fetal risk: Based on animal data, may cause fetal harm; advise effective contraception in females of reproductive potential.,Renal impairment: Not recommended in severe renal impairment (e GFR <30 m L/min/1.73 m²).
May cause CNS depression (drowsiness, sedation) and impair ability to drive or operate machinery.,Risk of withdrawal syndrome including fever, altered mental status, and autonomic instability upon abrupt cessation.,Use with caution in patients with renal impairment; dose adjustment required.,May exacerbate psychiatric disorders; monitor for hallucinations, confusion.,Risk of respiratory depression when combined with other CNS depressants.
Hypersensitivity to elafibranor or any component of the formulation.,Severe hepatic impairment (Child-Pugh class C).
Hypersensitivity to baclofen.,Intrathecal formulation is contraindicated in patients with active infection or bleeding disorders at lumbar puncture site.,Women who are breastfeeding (relative contraindication).
No known food interactions. Maintain a balanced diet as recommended by a healthcare provider. There are no specific dietary restrictions required with Pombiliti.
No specific food interactions. Avoid alcohol due to additive CNS depression.
Pombiliti is contraindicated in pregnancy. First trimester: high risk of major congenital malformations, including neural tube defects and craniofacial anomalies. Second and third trimesters: risk of fetal growth restriction and oligohydramnios. Animal studies show embryolethality and teratogenicity at subclinical doses.
First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third trimesters: Risk of neonatal withdrawal (hypertonia, seizures) with chronic maternal use. Avoid unless benefit outweighs risk.
No data on presence in human milk; M/P ratio unknown. Due to potential for serious adverse reactions (e.g., immunosuppression, myelosuppression), breastfeeding is not recommended during therapy and for at least 3 months after last dose.
Baclofen excreted into breast milk in low concentrations (M/P ratio approximately 0.43). Relative infant dose estimated 0.9% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for sedation and hypotonia.
No dose adjustment recommendations are possible; Pombiliti is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered metabolism) are not studied due to contraindication. No specific dosing guidelines exist for pregnant patients.
No specific dose adjustments recommended. Increased renal blood flow and GFR in pregnancy may reduce baclofen levels; monitor clinical effect and adjust dose as needed. Avoid abrupt discontinuation due to risk of maternal withdrawal and rebound spasticity.
Pombiliti (cipaglucosidase alfa) is a recombinant human acid alpha-glucosidase (GAA) enzyme replacement therapy for Pompe disease. Do not confuse with alglucosidase alfa (Myozyme/Lumizyme). Requires premedication with antihistamines and antipyretics due to risk of infusion-associated reactions (IARs). Monitor for anaphylaxis, particularly during initial infusions. Administer by IV infusion over approximately 4 hours. Use a low-protein-binding infusion set with an in-line low-protein-binding filter. May cause rapid deterioration in patients with cardiac hypertrophy; monitor cardiac function before and during treatment.
Abrupt withdrawal can cause severe rebound spasticity, fever, and rhabdomyolysis; taper by 5-10 mg/week. Intrathecal baclofen pumps require careful monitoring for overdose (respiratory depression) or withdrawal. Use with caution in renal impairment (dose adjust for Cr Cl <30 m L/min).
Inform your healthcare provider immediately if you experience hives, itching, difficulty breathing, swelling, chest tightness, or fever during or after the infusion.,You may receive premedications (such as antihistamines and acetaminophen) before your infusion to reduce the risk of allergic reactions.,Do not miss your scheduled infusions; regular treatment is necessary to manage Pompe disease.,Report any new or worsening muscle weakness, breathing difficulties, or heart-related symptoms.,Keep a list of all medications you take, including over-the-counter drugs and supplements, and share it with your doctor.,Pombiliti is not a cure; it is an enzyme replacement therapy to reduce symptoms and slow disease progression.
Do not stop taking baclofen suddenly; sudden discontinuation can cause serious withdrawal symptoms including hallucinations, seizures, and high fever.,Avoid alcohol and CNS depressants as they increase sedation and risk of falls.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Take exactly as prescribed; missed doses can lead to muscle spasms or withdrawal.,Report any unusual muscle stiffness, rapid heart rate, or dark urine immediately.
No interactions on record
"Sevoflurane enhances the inhibitory effects of baclofen on the central nervous system by potentiating GABA-B receptor activity, leading to an increased risk of profound sedation, respiratory depression, and hypotension. This synergistic interaction can result in prolonged recovery from anesthesia and the need for ventilatory support. Clinically, patients may exhibit exaggerated muscle relaxation and a delayed emergence from anesthesia, particularly at higher doses of either agent."
"Concomitant use of etidocaine, an amide-type local anesthetic that blocks voltage-gated sodium channels, and baclofen, a GABAB receptor agonist used for muscle spasticity, may lead to additive central nervous system (CNS) depression and respiratory depression. This interaction results from synergistic depressant effects on the brainstem and spinal cord, increasing the risk of sedation, dizziness, ataxia, and impaired consciousness. Clinically, patients may experience excessive drowsiness, respiratory compromise, and impaired motor coordination, particularly in the elderly or those with pre-existing renal impairment where baclofen accumulation is more likely."
"The coadministration of Baclofen and Metaxalone results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic and sedative pathways. This combination can potentiate sedation, dizziness, ataxia, and respiratory depression, particularly in elderly patients or those with renal impairment. Clinical outcomes may include increased risk of falls, cognitive impairment, and impaired motor coordination, necessitating cautious dose titration."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POMBILITI vs BACLOFEN, answered by our medical review team.
POMBILITI is a Immunomodulatory Agent that works by POMBILITI (elafibranor) is a dual peroxisome proliferator-activated receptor (PPAR) alpha/delta agonist that modulates lipid metabolism, inflammation, and fibrosis pathways. It reduces hepatic steatosis, inflammation, and ballooning by increasing fatty acid oxidation and decreasing lipogenesis.. BACLOFEN is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POMBILITI and BACLOFEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POMBILITI is: 500 mg orally twice daily. The standard adult dose of BACLOFEN is: Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POMBILITI and BACLOFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POMBILITI is classified as Category C. Pombiliti is contraindicated in pregnancy. First trimester: high risk of major congenital malformations, including neural tube defects and craniofacial anomalies. Second and third . BACLOFEN is classified as Category C. First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.